BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/30/2021 10:10:27 AM | Browse: 1122 | Download: 2463
Publication Name World Journal of Clinical Cases
Manuscript ID 59388
Country France
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report
Manuscript Source Unsolicited Manuscript
All Author List Jonathan Wong-Chong, Maureen Bernadach, Angeline Ginzac, Hugo Veyssière and Xavier Durando
ORCID
Author(s) ORCID Number
Jonathan Wong-Chong http://orcid.org/0000-0002-7385-5670
Maureen Bernadach http://orcid.org/0000-0002-7185-0809
Angeline Ginzac http://orcid.org/0000-0002-5614-0876
Hugo Veyssière http://orcid.org/0000-0003-2202-7362
Xavier Durando http://orcid.org/0000-0001-6035-3172
Funding Agency and Grant Number
Corresponding Author Hugo Veyssière, N/A, N/A, N/A, Division de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, 58 rue Montalembert, Clermont-Ferrand 63011, France. hugo.veyssiere@clermont.unicancer.fr
Key Words Thymic epithelial carcinoma; Programmed death-ligand 1 negative; Pembrolizumab; Immune checkpoint; Metastasis; Case report
Core Tip Thymic epithelial carcinomas are rare and have poor prognosis. The overall 5-year survival rate for patients with thymic carcinoma is about 30%–50%. We present the case of a 45-year-old Caucasian male who presented with hepatalgia and a cervical mass, and was diagnosed with programmed death-ligand 1-negative metastatic thymic carcinoma. The patient underwent pretreatment with platinum-based chemotherapy, after which pembrolizumab was administered as salvage therapy and complete metabolic response was achieved.
Publish Date 2021-01-30 10:10
Citation Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, Durando X. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World J Clin Cases 2021; 9(5): 1139-1147
URL https://www.wjgnet.com/2307-8960/full/v9/i5/1139.htm
DOI https://dx.doi.org/10.12998/wjcc.v9.i5.1139
Full Article (PDF) WJCC-9-1139.pdf
Full Article (Word) WJCC-9-1139.docx